Tag:
hepatitis B
Latest Headlines
Latest Headlines
Gilead drug clears hep B virus in chimpanzees
A new small molecule developed by Gilead Sciences has shown encouraging results in preclinical studies against hepatitis B--an infectious inflammatory illness of the liver caused by the virus of the same name--and is quickly moving toward the clinic.
After rejection, Dynavax to shoot for limited hep B vaccine approval
After rejecting Dynavax's ($DVAX) hepatitis B vaccine Heplisav for safety issues, the FDA said it will meet with the company in 6 weeks' time to discuss a more restricted use of the vaccine.
Dynavax regroups after FDA turns thumbs down on hep B vaccine Heplisav
Dynavax noted that regulators want to see further evaluation of safety in the broad age group of 18 to 70, pronouncing their concerns over the possibility of rare autoimmune events among patients taking the treatment and outlining questions on process validation and the manufacturing process.
French biotech rapidly stuck on losing side of hep C revolution
French biotech Transgene has watched partnership prospects vanish for its experimental vaccine against hepatitis C over the past year, as all-oral regimens against the liver-damaging disease have quickly taken over as the future therapy of choice.
Altravax pulls in $1.2M from NIH
NIH's National Institute of Allergy and Infectious Diseases has its eye on Altravax, awarding the company $1.2 million to advance a dengue vaccine and hepatitis B therapeutic.
Can Dynavax overcome Heplisav blow?
Two weeks ago, an FDA panel dealt a blow to Dynavax Technologies, raising concerns about the safety of the company's hepatitis B vaccine, Heplisav. Shares dropped and investors tend to turn their backs on a company when stock prices go down. But is the company's future really all that grim?
FDA panel concerned about safety of Dynavax's hep B vaccine
An FDA panel dealt a blow to Dynavax Technologies on Thursday, raising concerns about the safety of the company's hepatitis B vaccine.
Dynavax share price wilts after FDA panel snub
Dynavax Technologies ($DVAX) didn't get the safety nod it sought for its hepatitis B vaccine from FDA advisers Thursday, and its shares plummeted in extended trading. The Berkeley, CA-based biotech is seeking U.S. approval of the vaccine, Heplisav, which provides the developer its best shot at having a marketed product.
PerkinElmer snatches up Chinese molecular Dx outfit for $38M
PerkinElmer ($PKI) has become a much bigger player in China's molecular clinical diagnostics market with the wrap-up of its $38 million acquisition of Shanghai Haoyuan Biotech Co.
Startup biotech hauls in $23M A round for antiviral work
5AM Ventures and Canaan Partners have joined forces to lead a $23 million A round for a startup antiviral biotech based in Radnor, PA. Novira Therapeutics is developing capsid-targeting antivirals for hepatitis B and HIV.
